Advances in nucleic acid-based cancer vaccines
Journal of Biomedical Science,
Год журнала:
2025,
Номер
32(1)
Опубликована: Янв. 21, 2025
Abstract
Nucleic
acid
vaccines
have
emerged
as
crucial
advancements
in
vaccine
technology,
particularly
highlighted
by
the
global
response
to
COVID-19
pandemic.
The
widespread
administration
of
mRNA
against
billions
globally
marks
a
significant
milestone.
Furthermore,
approval
an
for
Respiratory
Syncytial
Virus
(RSV)
this
year
underscores
versatility
technology.
In
oncology,
combination
encoding
neoantigens
and
immune
checkpoint
inhibitors
(ICIs)
has
shown
remarkable
efficacy
eliciting
protective
responses
diseases
like
melanoma
pancreatic
cancer.
Although
use
DNA
been
limited
India,
inherent
stability
at
room
temperature
cost-effectiveness
present
viable
option
that
could
benefit
developing
countries.
These
advantages
may
help
address
some
challenges
associated
with
vaccines.
Currently,
several
trials
are
exploring
DNA-encoded
ICIs
across
various
cancer
types.
studies
highlight
promising
role
nucleic
acid-based
next
generation
immunotherapeutic
agents
treatment.
This
review
will
delve
into
recent
current
developmental
status
both
DNA-based
Язык: Английский
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer
Journal of Oncology Pharmacy Practice,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Objective
There
was
a
dire
need
to
construct
review
of
the
recent
developments
on
Immune
checkpoint
inhibitors
(ICIs),
CAR
T
Cells,
and
other
approaches
for
cell-based
immunotherapeutic
strategies
against
cancer
as
has
become
one
most
fatal
diseases
that
is
responsible
causing
several
deaths
per
annum.
Data
sources
Multiple
published
data
acquired
from
high-impact
factor
journal
articles.
summary
clinical
have
been
in
use
today
such
radiotherapy,
chemotherapy
immunotherapy
treat
different
types.
Among
novel
management
strategies,
role
by
cells
immensely
important.
Cancer
revolutionized
treatment
it
basically
utilizes
body's
immune
system
cancer.
At
forefront
this
revolution,
are
considered
fundamental
components
system.
Conclusions
The
current
explores
therapeutic
potential
fight
applying
various
ICIs
(PD-1/PD-L1,
CTLA-4,
TIGIT,
BTLA,
TIM3,
LAG3)
adoptive
cell
therapy.
stimulate
existing
anti-tumor
T-cell
response
way
removing
inhibitors.
On
hand,
therapy
(ACT)
patient's
modified
identify
attack
tumor
cells.
Furthermore,
also
highlights
significant
successes
observed
with
these
therapies,
notably
PD-1
blockade
tumors.
Moreover,
vaccination,
bispecific
antibodies
cytokine
enhance
antitumor
activity.
Therapeutic
vaccines
expose
tumor-associated
antigens
training
then
cells,
showing
promising
results
types
cancers
prostate
melanoma.
While,
accompanied
cytokines
interleukin-2
(IL-2)
activity
proliferation,
thereby
boosting
overall
response.
Lastly,
future
immunotherapy,
envisioning
advancements
design
gene
editing
techniques
can
efficacy
across
broader
spectrum
cancers.
Язык: Английский
Vaccination and personalized cancer vaccines focusing on common cancers in women: a narrative review
Pathology - Research and Practice,
Год журнала:
2025,
Номер
270, С. 155983 - 155983
Опубликована: Апрель 18, 2025
Язык: Английский
Peptide Vaccines in Cancer Immunotherapy
Neeraj Kumar Chouhan,
Mamta N. Talati,
Mani Sharma
и другие.
Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Год журнала:
2024,
Номер
unknown, С. 235 - 264
Опубликована: Авг. 28, 2024
Peptide
vaccines
offer
promise
in
cancer
immunotherapy,
leveraging
specificity,
safety,
and
the
potential
for
targeted
immune
responses
against
tumors.
By
incorporating
multiple
epitopes,
they
enhance
recognition
can
be
customized
based
on
individual
patient
profiles.
This
chapter
explores
peptide
vaccines,
emphasizing
adjuvants
that
efficacy
while
balancing
safety.
Traditional
like
alum
oil-in-water
emulsions
promote
cell
activation,
toll-like
receptor
agonists
stimulate
innate
immunity.
Strategies
to
improve
include
combining
with
other
agents
overcoming
challenges
low
immunogenicity.
Future
research
should
refine
adjuvant
formulations
explore
combination
therapies
maximize
effectiveness
of
cancer.
Язык: Английский